| ECASX | RPTIX | ECASX / RPTIX | |
| Total Expense Ratio | 1.87 | 0.63 | 297% |
| Annual Report Gross Expense Ratio | 1.87 | 0.63 | 297% |
| Fund Existence | 16 years | 10 years | - |
| Gain YTD | -6.433 | 3.369 | -191% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 500000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 12.6B | 25.9B | 49% |
| Annual Yield % from dividends | 0.00 | 0.05 | - |
| Returns for 1 year | -16.18 | -8.70 | 186% |
| Returns for 3 years | -4.85 | 10.44 | -46% |
| Returns for 5 years | -3.53 | -6.04 | 59% |
| Returns for 10 years | 11.69 | 31.48 | 37% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AMDG | 45.02 | 6.83 | +17.88% |
| Leverage Shares 2X Long AMD Daily ETF | |||
| HQL | 16.98 | 0.22 | +1.31% |
| abrdn Life Sciences Investors | |||
| BTA | 9.56 | 0.01 | +0.10% |
| Blackrock Long-Term Municipal Advantage Trust | |||
| JMST | 50.92 | 0.01 | +0.02% |
| JPMorgan Ultra-Short Municipal Inc ETF | |||
| HELX | 34.90 | N/A | N/A |
| Franklin Genomic Advancements ETF | |||